Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol

Respiratory Research, Jan 2006

Background To compare the efficacy and safety of budesonide/formoterol (Symbicort®) with formoterol (Oxis®) in the treatment of patients with acute asthma who showed evidence of refractoriness to short-acting β2-agonist therapy. Methods In a 3 hour, randomized, double-blind study, a total of 115 patients with acute asthma (mean FEV1 40% of predicted normal) and a refractory response to salbutamol (mean reversibility 2% of predicted normal after inhalation of 400 μg), were randomized to receive either budesonide/formoterol (320/9 μg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 1280/36 μg]) or formoterol (9 μg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 36 μg]). The primary efficacy variable was the average FEV1 from the first intake of study medication to the measurement at 90 minutes. Secondary endpoints included changes in FEV1 at other timepoints and change in respiratory rate at 180 minutes. Treatment success, treatment failure and patient assessment of the effectiveness of the study medication were also measured. Results FEV1 increased after administration of the study medication in both treatment groups. No statistically significant difference between the treatment groups was apparent for the primary outcome variable, or for any of the other efficacy endpoints. There were no statistically significant between-group differences for treatment success, treatment failure or patient assessment of medication effectiveness. Both treatments were well tolerated. Conclusion Budesonide/formoterol and formoterol provided similarly rapid relief of acute bronchoconstriction in patients with asthma who showed evidence of refractoriness to a short-acting β2-agonist.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://respiratory-research.com/content/pdf/1465-9921-7-13.pdf

Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol

ED Bateman 1 L Fairall 1 DM Lombardi 0 R English 1 0 Hospital Municipal de Rehabilitacion Respiratoria 'Maria Ferrer' , Buenos Aires , Argentina 1 University of Cape Town Lung Institute , Cape Town , South Africa Background: To compare the efficacy and safety of budesonide/formoterol (Symbicort) with formoterol (Oxis) in the treatment of patients with acute asthma who showed evidence of refractoriness to short-acting 2-agonist therapy. Methods: In a 3 hour, randomized, double-blind study, a total of 115 patients with acute asthma (mean FEV1 40% of predicted normal) and a refractory response to salbutamol (mean reversibility 2% of predicted normal after inhalation of 400 g), were randomized to receive either budesonide/ formoterol (320/9 g, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 1280/36 g]) or formoterol (9 g, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 36 g]). The primary efficacy variable was the average FEV1 from the first intake of study medication to the measurement at 90 minutes. Secondary endpoints included changes in FEV1 at other timepoints and change in respiratory rate at 180 minutes. Treatment success, treatment failure and patient assessment of the effectiveness of the study medication were also measured. Results: FEV1 increased after administration of the study medication in both treatment groups. No statistically significant difference between the treatment groups was apparent for the primary outcome variable, or for any of the other efficacy endpoints. There were no statistically significant between-group differences for treatment success, treatment failure or patient assessment of medication effectiveness. Both treatments were well tolerated. Conclusion: Budesonide/formoterol and formoterol provided similarly rapid relief of acute bronchoconstriction in patients with asthma who showed evidence of refractoriness to a shortacting 2-agonist. - Introduction Patients presenting with symptoms of acute asthma are traditionally treated with short-acting 2-agonists [1,2]. Formoterol is a long-acting 2-agonist with a rapid onset of action, producing bronchodilation within 13 minutes of inhalation [3-5]. This effect is comparable with that of salbutamol [5], making formoterol suitable for the treatment of acute asthma. In this setting, formoterol has proved both safe and efficacious [6,7]. A large study performed in an emergency room setting by Boonsawat and colleagues [6] showed that high-dose formoterol was as rapid and effective as high-dose salbutamol in reversing bronchoconstriction in patients with severe asthma, but formoterol produced greater improvements than salbutamol in lung function over 4 hours. For this reason, formoterol has been licensed for use as both maintenance therapy and as an alternative to salbutamol and terbutaline for the relief of acute asthma symptoms. Asthma patients experiencing acute symptoms may use their 2-agonist reliever medication repeatedly. This can result in downregulation of 2-receptors and consequent relative refractoriness to the bronchodilatory effects of this class of drug [8,9]. High doses of inhaled corticosteroid (ICS) have been reported to upregulate these receptors and restore 2-agonist responsiveness [10]. In order to study the potential of this favourable interaction, Pansegrouw [11] examined the use of combined ICS and short-acting 2-agonist treatment in patients with acute asthma who initially showed no response to 2-agonist therapy. It was reported that 'priming' patients with ICS before commencing nebulised 2-agonist treatment was more effective than therapy with the 2-agonist alone at improving features of the exacerbation, including lung function [11]. Although, to our knowledge, this study has not been repeated, it raises the prospect that budesonide and formoterol which are now available together in a combination inhaler (Symbicort; budesonide/formoterol) may be more effective than formoterol given alone in treating patients with acute asthma who initially show no response to 2-agonist therapy. The present study was designed to compare the efficacy of budesonide/formoterol with that of formoterol for the treatment of patients with acute asthma who had evidence of relative refractoriness to the administration of a short-acting 2-agonist. Patients and methods Patients Patients aged 12 years presenting with acute asthma were recruited from a total of 8 centres in Argentina, Mexico and South Africa. All patients were required to have asthma, as defined by the American Thoracic Society criteria (including symptoms of wheeze, episodic cough, and dyspnea) [12], with a pre-bronchodilator forced expiratory volume in 1 second (FEV1; measured on arrival in the Formoterol (n = 57) Budesonide/formoterol (n = 58) All values are presented as absolute numbers or as means, except asthma duration, for which the median is given. aDose of inhaled corticosteroid (budesonide equivalents) (...truncated)


This is a preview of a remote PDF: http://respiratory-research.com/content/pdf/1465-9921-7-13.pdf

ED Bateman, L Fairall, DM Lombardi, R English. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol, Respiratory Research, 2006, pp. 13, 7, DOI: 10.1186/1465-9921-7-13